A review of a bi-layered living cell treatment (Apligraf�) in the treatment of venous leg ulcers and diabetic foot ulcers

Zaulyanov, Larissa; Kirsner, Robert S.

doi:10.2147/ciia.2007.2.1.93

Cited by 219 publications

(148 citation statements)

References 37 publications

(39 reference statements)

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Apligraf (Organogenesis Inc., Canton, MA, USA), is a bilayered bioengineered skin substitute (BBSS) containing a dermal layer of human fibroblasts in a bovine type I collagen lattice and an epidermal layer formed by human keratinocytes (25)(26)(27)(28). Neonatal human foreskin is the source for the fibroblasts and keratinocytes, and Apligraf is FDA approved for treatment of partial & full-thickness skin ulcers due to venous insufficiency and DFU that have not appropriately responded to conventional therapy.…”

Section: Human Skin Allografts and Bioengineered Skin Substitutesmentioning

confidence: 99%

An update and review of cell-based wound dressings and their integration into clinical practice

Pourmoussa¹,

Gardner²,

Johnson³

et al. 2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Chronic wounds affect over 4 million individuals and pose a significant burden to the US healthcare system. Diabetes, venous stasis, radiation or paralysis are common risk factors for chronic wounds. Unfortunately, the current standard of care (SOC) has a high relapse rate and these wounds continue to adversely affect patients' quality of life. Fortunately, advances in tissue engineering have allowed for the development of cell-based wound dressings that promote wound healing by improving cell migration and differentiation. As the available options continue to increase in quantity and quality, physicians should have a user-friendly guide to reference when deciding which dressing to use. The objective of this review is to identify the currently available biologic dressings, describe their indications, and provide a framework for integration into clinical practice. This review included 53 studies consisting of prospective and retrospective cohorts as well as several randomized control trials. Three general categories of cell-based biologic dressings were identified and nine brands were included. Cell-based biologic dressings have shown efficacy in a broad range of scenarios, and studies examining their efficacy have improved our understanding of the pathophysiology of chronic wounds. Amniotic and placental membranes have the widest scope and can be used to treat all subtypes of chronic wounds. Human skin allografts and bioengineered skin substitutes can be used for chronic ulcers but generally require a vascularized wound bed. Autologous platelet rich plasma (PRP) has shown promise in venous stasis ulcers and decubitus ulcers that have failed conventional treatment. Overall, more research is necessary to determine if these novel therapeutic options will change the current SOC, but current studies demonstrate encouraging results in the treatment of chronic wounds.

show abstract

Section: Human Skin Allografts and Bioengineered Skin Substitutesmentioning

confidence: 99%

An update and review of cell-based wound dressings and their integration into clinical practice

Pourmoussa¹,

Gardner²,

Johnson³

et al. 2016

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…Apligraf ® is supplied as needed, in one size, with a shelf-life of 10 days. It was FDA-approved in 1998 for use in conjunction with compression therapy for the treatment of non-infected, partial-and full-thickness skin ulcers [26].…”

Section: Apligraf ® (Organogenesis)mentioning

confidence: 99%

Mucosal Substitutes for Periodontal Soft Tissue Regeneration

PK¹

2015

Dentistry

View full text Add to dashboard Cite

“…Research in this field is currently flourishing, and each month brings its lot of newly demonstrated capacity for differentiation. For skin grafting, current techniques provide essentially two types of cells, basal keratinocytes for epidermis and fibroblasts for dermis [32]. The host provides additional migratory cells, in particular monocyte-derived Langerhans cells and blood vessels-forming cells.…”

Section: What Can Pluripotent Stem Cells Do For Our Skin Beyond Keratmentioning

confidence: 99%

Concise Review: Epidermal Grafting: The Case for Pluripotent Stem Cells

Nissan¹,

Baldeschi

Peschanski

2011

Stem Cells

View full text Add to dashboard Cite

Although cell therapy has been clinically implemented for several decades, its use is hampered by the difficulty in supplying the amount of epidermal substitute needed to extend the application to all patients who may benefit from it. How human pluripotent stem cells may help meet this challenge is the topic of this review. After reporting on the main current applications and needs of skin grafting, we explore the potential of pluripotent stem cells—either of embryonic origin or produced by genetic reprogramming—to provide the needed clinical-grade keratinocytes, fulfilling industrial scale production, and quality standards. Immunogenicity is clearly an issue, although one may expect cells displaying characteristics of fetal or embryonic skin to have a much better tolerance than adult keratinocytes. The open possibility of a bank of pluripotent stem cell lines selected on the basis of interesting haplotypes may eventually provide a definitive answer. Actually, making the case for pluripotent stem cells in skin grafting goes well beyond that specific cell type. Most cell phenotypes that normally participate to the formation of dermis and epidermis can either already be obtained through in vitro differentiation from pluripotent stem cells or would likely migrate from the host into a graft. However, differentiation protocols for specialized glands and hair follicles remain to be designed. A future can be foreseen when reconstructive medicine will make use of composite grafts integrating several different cell types and biomaterials.

show abstract

A review of a bi-layered living cell treatment (Apligraf�) in the treatment of venous leg ulcers and diabetic foot ulcers

Cited by 219 publications

References 37 publications

An update and review of cell-based wound dressings and their integration into clinical practice

An update and review of cell-based wound dressings and their integration into clinical practice

Mucosal Substitutes for Periodontal Soft Tissue Regeneration

Concise Review: Epidermal Grafting: The Case for Pluripotent Stem Cells

Contact Info

Product

Resources

About